Significant effort has been focused on developing renally-clearable nanoparticle agents since efficient renal clearance is important for eventual clinical translation. Silver sulfide nanoparticles (AgS-NP) have recently been identified as contrast agents for dual energy mammography, computed tomography (CT) and fluorescence imaging and probes for drug delivery and photothermal therapy with good biocompatibility. However, most AgS-NP reported to date are not renally excretable and are observed to accumulate and remain in the reticuloendothelial system (RES) organs, liver and spleen, for a long time, which could negatively impact their likelihood for translation. Herein, we present renally-clearable, 3.1 nm AgS-NP with 85% of the injected dose (ID) being excreted within 24 hours of intravenous injection, which is amongst the best clearance of similarly sized nanoparticles reported thus far (mostly between 20-75% of ID). The urinary excretion and low RES accumulation of these nanoparticles in mice were indicated by in vivo CT imaging and biodistribution analysis. In summary, these ultrasmall AgS-NP can be effectively eliminated via urine and have high translational potential for various biomedical applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523639PMC
http://dx.doi.org/10.1021/acs.chemmater.9b01750DOI Listing

Publication Analysis

Top Keywords

renally excretable
8
silver sulfide
8
sulfide nanoparticles
8
mammography computed
8
computed tomography
8
excretable size-tunable
4
size-tunable silver
4
nanoparticles
4
nanoparticles dual-energy
4
dual-energy mammography
4

Similar Publications

Pseudohaematuria Due to Mesalazine: A Case Report.

Nephrology (Carlton)

January 2025

School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

The symptom of macroscopic or 'visible' haematuria can cause significant patient distress, largely due to its' potential association with urinary tract malignancy, infection or glomerular disease. This lesson from practice describes the case of a 19-year-old female patient for whom the cause of red/brown urinary discolouration was found to relate to a reaction between renally excreted mesalazine and domestic bleach in the toilet bowel. Recognition of this phenomenon in patients taking mesalazine for inflammatory colitis is important to minimise patient distress and unnecessary investigation for a urinary tract cause.

View Article and Find Full Text PDF

2-Phenoxyethanol (PhE) is an amphiphilic organic compound frequently used as a broad-spectrum preservative in cosmetic products and other consumer goods. PhE is also used as a biocidal component in occupational settings. A previous volunteer study by our working group following oral exposure to PhE showed that PhE is almost completely taken up into the human body followed by an extensive metabolization and fast urinary elimination.

View Article and Find Full Text PDF
Article Synopsis
  • Fabry disease is an X-linked lysosomal disorder causing complications like kidney issues and challenges with drug elimination, prompting the need to study migalastat in patients with end-stage renal disease (ESRD) on dialysis.
  • This study tested a 123 mg dose of migalastat in ESRD patients compared to controls with normal kidney function, examining its pharmacokinetics, how well it's cleared during dialysis, and its tolerability.
  • Results showed that migalastat is largely removed by dialysis and suggested dosing regimens for ESRD patients that could maintain effective drug levels while minimizing accumulation in tissues.
View Article and Find Full Text PDF
Article Synopsis
  • Contrast-enhanced dual-energy mammography (DEM) can detect tumors better in dense breast tissue than standard mammography, but traditional iodine-based contrast agents have significant limitations, including use restrictions and high doses.* -
  • The study introduces ultrasmall molybdenum disulfide nanoparticles (MoS NPs) that are biocompatible and produce higher image contrast in DEM compared to conventional contrast agents like iopamidol.* -
  • MoS NPs also show rapid elimination from the body, reducing concerns about long-term toxicity, which suggests they could effectively serve as dual-modality contrast agents for both DEM and CT imaging.*
View Article and Find Full Text PDF

Background: Paxlovid is a combination of the antiviral agents nirmatrelvir and ritonavir indicated for the oral treatment of high-risk, symptomatic patients with coronavirus disease 2019 (COVID-19). As real-world data on the plasma concentrations of nirmatrelvir/ritonavir (Paxlovid) are limited, the aim of this study was to investigate nirmatrelvir/ritonavir plasma trough levels in a clinical setting using therapeutic drug monitoring.

Methods: A prospective, noninterventional, multicenter, observational clinical study was conducted in which the plasma trough levels of nirmatrelvir/ritonavir were simultaneously determined by using liquid chromatography tandem mass spectrometry in patients with symptomatic COVID-19.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!